Ipsen S.A. (EPA:IPN)

Market Cap	14.01B +65.2%
Revenue (ttm)	3.93B +9.9%
Net Income	443.50M +28.2%
EPS	5.32 +28.2%
Shares Out	82.10M
PE Ratio	32.09
Forward PE	12.41
Dividend	1.40 (0.82%)
Ex-Dividend Date	Jun 3, 2026

Volume	68,410
Open	170.80
Previous Close	171.10
Day's Range	166.50 - 172.40
52-Week Range	101.20 - 173.50
Beta	0.32
Analysts	Buy
Price Target	160.00 (-6.27%)
Earnings Date	Jul 30, 2026

About Ipsen

Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience in North America, Europe, and internationally. It engages in the development of Somatuline for neuroendocrine tumors and acromegaly indications; and Dysport for motor muscular disorders and medical aesthetics indications; and Decapeptyl for advanced metastatic prostate cancer, uterine fibroids, central precocious puberty, endometriosis, female infertility, and early-stage breast cancer in combination with hormo...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1929
• Employees: 5,535
• Stock Exchange: Euronext Paris
• Ticker Symbol: IPN

Financial Performance

In 2025, Ipsen's revenue was 3.93 billion, an increase of 9.92% compared to the previous year's 3.57 billion. Earnings were 443.50 million, an increase of 28.22%.

Analyst Summary

According to 15 analysts, the average rating for IPN stock is "Buy." The 12-month stock price target is €160.00, which is a decrease of -6.27% from the latest price.

Price Target

€160.00

(-6.27% downside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 3, 2026

Data Sources Report a data error